Events
Tafalgie Therapeutics at Bio Convention 2025 !
Tafalgie Therapeutics at BIO 2025! We are pleased to announce our presence at BIO Convention 2025, the must-attend event for ... Show more
Tafalgie Therapeutics appoints Tanja Ouimet to its Supervisory Board
Tafalgie Therapeutics appoints Tanja Ouimet to its Supervisory Board Tafalgie Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of ... Show more
Departmental prize for research in Provence 2024
Departmental prize for research in Provence 2024 Aziz Moqrich, CNRS Research Director, Vice-President and Scientific Director of Tafalgie Therapeutics, receives ... Show more
Tafalgie Therapeutics selected as a finalist for the regional EY Entrepreneur of the Year 2024 award
Tafalgie Therapeutics selected as a finalist for the regional EY Entrepreneur of the Year 2024 award On Thursday, September 19, ... Show more
Tafalgie Therapeutics is growing !
Tafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specializing in the development ... Show more
Participating in the “IPOready 2024” program
Tafalgie Therapeutics will participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year ... Show more
The SATT IMPACT 2022 Prize on the TAFA4 Protein
Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 protein . Dr ... Show more